Ciphergen Sales Stall in Q4 After Tools Business Divestiture | GenomeWeb
NEW YORK (GenomeWeb News) — Ciphergen’s fourth-quarter revenues plunged 440 percent as R&D spending fell 9 percent and losses decreased 80 percent, the company said today.
Total receipts for the three months ended Dec. 31 decreased to $1.2 million from $6.6 million year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.